| AVALO THERAPEUTICS |
| USA |
| Gesundheit |
| US05338F3064 / A3E2FR |
| C6K0 (Frankfurt) / AVTX (NASDAQ) |
| FRA:C6K0, ETR:C6K0, C6K0:GR, NASDAQ:AVTX |
| - |
| https://www.avalotx.com/ |
|
Avalo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases with significant unmet needs. The company targets the IL-1β pathway, a central driver of infl..
>Volltext.. |
| 329.69 Mio. EUR |
| 248.04 Mio. EUR |
| 0.05 Mio. EUR |
| -62.88 Mio. EUR |
| -67.8 Mio. EUR |
| -5.28 EUR |
| 2.1 Mio. EUR |
| 13.77 Mio. EUR |
| -44.58 Mio. EUR |
| 7.6 |
| -88.21% |
| -96.36% |
| - |
| - |
| - |
| AVALO THERAPEUTICS, AVALO THERAPEUTIC |
| 05.04.26 |
|